nach oben

Journal of Mammary Gland Biology and Neoplasia

Erschienen in:

04.01.2021 | Breast Cancer

Cancer-Associated Fibroblasts in the Breast Tumor Microenvironment

verfasst von: María Belén Giorello, Francisco Raúl Borzone, Vivian Labovsky, Flavia Valeria Piccioni, Norma Alejandra Chasseing

Erschienen in: Journal of Mammary Gland Biology and Neoplasia | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Years of investigation have shed light on a theory in which breast tumor epithelial cells are under the effect of the stromal microenvironment. This review aims to discuss recent findings concerning the phenotypic and functional characteristics of cancer associated fibroblasts (CAFs) and their involvement in tumor evolution, as well as their potential implications for anti-cancer therapy. In this manuscript, we reviewed that CAFs play a fundamental role in initiation, growth, invasion, and metastasis of breast cancer, and also serve as biomarkers in the clinical diagnosis, therapy, and prognosis of this disease.

Lorusso G, Rüegg C. The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem Cell Biol. 2008;130:1091–103. https://doi.org/10.1007/s00418-008-0530-8.CrossRefPubMed

Bissell MJ, Radisky DC, Rizki A, et al. The organizing principle: Microenvironmental influences in the normal and malignant breast. Differ. 2002;70:537–46. https://doi.org/10.1046/j.1432-0436.2002.700907.x.CrossRef

Arendt LM, Rudnick JA, Keller PJ, et al. Stroma in breast development and disease. Semin Cell Dev Biol. 2010;21:11–8. https://doi.org/10.1016/j.semcdb.2009.10.003.CrossRefPubMed

Chantrain CF, Feron O, Marbaix E, et al. Bone marrow microenvironment and tumor progression. Cancer Microenviron. 2008;1:23–35. https://doi.org/10.1007/s12307-008-0010-7.CrossRefPubMedPubMedCentral

Gao D, Mittal V. The role of bone-marrow-derived cells in tumor growth, metastasis initiation and progression. Trends Mol Med. 2009;15:333–43. https://doi.org/10.1016/j.molmed.2009.06.006.CrossRefPubMed

Gonda TA, Varro A, Wang TC, et al. Molecular biology of cancer-associated fibroblasts: Can these cells be targeted in anti-cancer therapy? Semin Cell Dev Biol. 2010;21:2–10. https://doi.org/10.1016/j.semcdb.2009.10.001.CrossRefPubMed

Spaeth EL, Dembinski JL, Sasser AK, et al. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS ONE. 2009;4:e4992.CrossRefPubMedPubMedCentral

Martin FT, Dwyer RM, Kelly J, et al. Potential role of mesenchymal stem cells (MSCs) in the breast tumour microenvironment: Stimulation of epithelial to mesenchymal transition (EMT). Breast Cancer Res Treat. 2010;124:317–26. https://doi.org/10.1007/s10549-010-0734-1.CrossRefPubMed

Rhodes LV, Muir SE, Elliott S, et al. Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence. Breast Cancer Res Treat. 2010;121:293–300. https://doi.org/10.1007/s10549-009-0458-2.CrossRefPubMed

10.

El-Haibi CP, Karnoub AE. Mesenchymal stem cells in the pathogenesis and therapy of breast cancer. J Mammary Gland Biol Neoplas. 2010;15:399–409. https://doi.org/10.1007/s10911-010-9196-7.CrossRef

11.

Klopp AH, Gupta A, Spaeth E, et al. Concise review: Dissecting a discrepancy in the literature: Do mesenchymal stem cells support or suppress tumor growth? Stem Cells. 2011;29:11–9. https://doi.org/10.1002/stem.559.CrossRefPubMed

12.

Luo H, Tu G, Liu Z, et al. Cancer-associated fibroblasts: A multifaceted driver of breast cancer progression. Cancer Lett. 2015;361:155–63. https://doi.org/10.1016/j.canlet.2015.02.018.CrossRefPubMed

13.

Paulsson J, Micke P. Prognostic relevance of cancer-associated fibroblasts in human cancer. Semin Cancer Biol. 2014;25:61–8. https://doi.org/10.1016/j.semcancer.2014.02.006.CrossRefPubMed

14.

Kaushik N, Kim S, Suh Y, et al. Proinvasive extracellular matrix remodeling for tumor progression. Arch Pharmacal Res. 2019;42:40–7. https://doi.org/10.1007/s12272-018-1097-0.CrossRef

15.

Najafi M, Goradel NH, Farhood B, et al. Tumor microenvironment: Interactions and therapy. J Cell Physiol. 2019;234:5700–21. https://doi.org/10.1002/jcp.27425.CrossRefPubMed

16.

Morsing M, Klitgaard MC, Jafari A, et al. Evidence of two distinct functionally specialized fibroblast lineages in breast stroma. Breast Cancer Res. 2016;18:1–11. https://doi.org/10.1186/s13058-016-0769-2.CrossRef

17.

Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006;6:392–401. https://doi.org/10.1038/nrc1877.CrossRefPubMed

18.

Yoshida GJ. Regulation of heterogeneous cancer-associated fibroblasts: the molecular pathology of activated signaling pathways. J Exp & Clin Cancer Res. 2020;39:112. https://doi.org/10.1186/s13046-020-01611-0.CrossRef

19.

Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16:582–98. https://doi.org/10.1038/nrc.2016.73.CrossRefPubMed

20.

LeBleu VS, Kalluri R. A peek into cancer-associated fibroblasts: origins, functions and translational impact. Disease models & mechanisms. 2018;11:dmm029447. https://doi.org/10.1242/dmm.029447.

21.

Yoshida GJ, Azuma A, Miura Y, et al. Activated fibroblast program orchestrates tumor initiation and progression; molecular mechanisms and the associated therapeutic strategies. Int J Mol Sci. 2019;20:2256. https://doi.org/10.3390/ijms20092256.CrossRefPubMedCentral

22.

Barbazán J, Matic VD. Cancer associated fibroblasts: is the force the path to the dark side? Curr Opin Cell Biol. 2019;56:71–9. https://doi.org/10.1016/j.ceb.2018.09.002.CrossRefPubMed

23.

Salimifard S, Masjedi A, Hojjat-Farsangi M, et al. Cancer associated fibroblasts as novel promising therapeutic targets in breast cancer. Pathol Res Pract. 2020;216:152915. https://doi.org/10.1016/j.prp.2020.152915.CrossRefPubMed

24.

Shekhar MPV, Pauley R, Heppner G. Extracellular matrix-stromal cell contribution to neoplastic phenotype of epithelial cells in the breast. Breast Cancer Res. 2003;5:130–5. https://doi.org/10.1186/bcr580.CrossRefPubMedPubMedCentral

25.

Giatromanolaki A, Sivridis E, Koukourakis MI. The pathology of tumor stromatogenesis. Cancer Biol Ther. 2007;6:639–45. https://doi.org/10.4161/cbt.6.5.4198.CrossRefPubMed

26.

Bitoux M-A, Stamenkovic I. Tumor-host interactions: the role of inflammation. Histochem Cell Biol. 2008;130:1079–90. https://doi.org/10.1007/s00418-008-0527-3.CrossRefPubMed

27.

Garamszegi N, Garamszegi SP, Shehadeh LA, et al. Extracellular Matrix-Induced Gene Expression in Human Breast Cancer Cells. Mol Cancer Res. 2009;7:319–29. https://doi.org/10.1158/1541-7786.MCR-08-0227.CrossRefPubMedPubMedCentral

28.

Ali S, Lazennec G. Chemokines: Novel targets for breast cancer metastasis. Cancer Metastasis Rev. 2007;26:401–20. https://doi.org/10.1007/s10555-007-9073-z.CrossRefPubMedPubMedCentral

29.

Ahn S, Cho J, Sung J, et al. The prognostic significance of tumor-associated stroma in invasive breast carcinoma. Tumor Biol. 2012;33:1573–80. https://doi.org/10.1007/s13277-012-0411-6.CrossRef

30.

Hugo HJ, Lebret S, Tomaskovic-Crook E, et al. Contribution of fibroblast and mast cell (afferent) and tumor (efferent) IL-6 effects within the tumor microenvironment. Cancer Microenviron. 2012;5:83–93. https://doi.org/10.1007/s12307-012-0098-7.CrossRefPubMedPubMedCentral

31.

Horimoto Y, Polanska UM, Takahashi Y, et al. Emerging roles of the tumor-associated stroma in promoting tumor metastasis. Cell Adhes Migr. 2012;6:193–202. https://doi.org/10.4161/cam.20631.CrossRef

32.

Conklin MW, Eickhoff JC, Riching KM, et al. Aligned collagen is a prognostic signature for survival in human breast carcinoma. Am J Pathol. 2011;178:1221–32. https://doi.org/10.1016/j.ajpath.2010.11.076.CrossRefPubMedPubMedCentral

33.

Conklin MW, Keely PJ. Why the stroma matters in breast cancer: Insights into breast cancer patient outcomes through the examination of stromal biomarkers. Cell Adhes Migr. 2012;6:249–60. https://doi.org/10.4161/cam.20567.CrossRef

34.

Hill BS, Sarnella A, D’Avino G, et al. Recruitment of stromal cells into tumour microenvironment promote the metastatic spread of breast cancer. Semin Cancer Biol. 2019;60:202–13. https://doi.org/10.1016/j.semcancer.2019.07.028.CrossRefPubMed

35.

Yeldag G, Rice A, del Río HA. Chemoresistance and the Self-Maintaining Tumor Microenvironment. Cancers. 2018;10:471. https://doi.org/10.3390/cancers10120471.CrossRefPubMedCentral

36.

Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discovery. 2019;18:99–115. https://doi.org/10.1038/s41573-018-0004-1.CrossRefPubMed

37.

Gillies RJ, Raghunand N, Karczmar GS, et al. MRI of the tumor microenvironment. J Magn Reson Imaging. 2002;16:430–50. https://doi.org/10.1002/jmri.10181.CrossRefPubMed

38.

Wouters BG, Weppler SA, Koritzinsky M, et al. Hypoxia as a target for combined modality treatments. 2002;38:1–9.

39.

Runkel S, Wischnik A, Teubner J, Kaven E, Gaa J MF. Oxygenation of Mammary Tumors as Evaluated by Ultrasound-Guided Computerized-PO2-Histography. In Oxygen Transport to Tissue XV. Springer, Boston, MA. 1994. p. 451–8. https://doi.org/10.1007/978-1-4615-2468-7_60.

40.

Knoop C, Hockel M. Oxygenation of Human Tumors: Evaluation Of Tissue Oxygen Distribution In Breast Cancers By Computerized O2 Tension Measurements. Can Res. 1991;51:3316–22.

41.

Mccarty MF, Whitaker J. Manipulating Tumor Acidification As Cancer Treament Strategys. 2010;15:264–72.

42.

De Wever O, Mareel M. Role of tissue stroma in cancer cell invasion. J Pathol. 2003;200:429–47. https://doi.org/10.1002/path.1398.CrossRefPubMed

43.

Bishop J. Molecular themes in oncogenesis. Cell. 1991;64:235–48. https://doi.org/10.1016/0092-8674(91)90636-d.CrossRefPubMed

44.

Liotta LA, Kohn EC. The microenvironment of the tumour–host interface. Nat. 2001;411:375–9. https://doi.org/10.1038/35077241.CrossRef

45.

Dolberg DS, Hollingsworth R, Hertle M, et al. Wounding and its role in RSV-mediated tumor formation. Sci. 1985;230:676–8. https://doi.org/10.1126/science.2996144.CrossRef

46.

Sieweke MH, Thompson NL, Sporn MB, et al. Mediation of wound-related rous sarcoma virus tumorigenesis by TGF-β. Sci. 1990;248:1656–60. https://doi.org/10.1126/science.2163544.CrossRef

47.

Pietras K, Östman A. Hallmarks of cancer: Interactions with the tumor stroma. Exp Cell Res. 2010;316:1324–31. https://doi.org/10.1016/j.yexcr.2010.02.045.CrossRefPubMed

48.

Sappino A ‐P, Skalli O, Jackson B, et al. Smooth‐muscle differentiation in stromal cells of malignant and non‐malignant breast tissues. Int J Cancer. 1988;41:707–12. https://doi.org/10.1002/ijc.2910410512.

49.

Ishii G, Ochiai A, Neri S. Phenotypic and functional heterogeneity of cancer-associated fibroblast within the tumor microenvironment. Adv Drug Deliv Rev. 2016;99:186–96. https://doi.org/10.1016/j.addr.2015.07.007.CrossRefPubMed

50.

Qiao A, Gu F, Guo X, et al. Breast cancer-associated fibroblasts: their roles in tumor initiation, progression and clinical applications. Front Med. 2016;10:33–40. https://doi.org/10.1007/s11684-016-0431-5.CrossRefPubMed

51.

Kumar S, Shabi TS, Goormaghtigh E. A FTIR imaging characterization of fibroblasts stimulated by various breast cancer cell lines. PLoS ONE. 2014;9. https://doi.org/10.1371/journal.pone.0111137.

52.

Shiga K, Hara M, Nagasaki T, et al. Cancer-associated fibroblasts: Their characteristics and their roles in tumor growth. Cancers. 2015;7:2443–58. https://doi.org/10.3390/cancers7040902.CrossRefPubMedPubMedCentral

53.

Buchsbaum RJ, Oh SY. Breast cancer-associated fibroblasts: Where we are and where we need to go. Cancers. 2016;8:1–19. https://doi.org/10.3390/cancers8020019.CrossRef

54.

Park SY, Kim HM, Koo JS. Differential expression of cancer-associated fibroblast-related proteins according to molecular subtype and stromal histology in breast cancer. Breast Cancer Res Treat. 2015;149:727–41. https://doi.org/10.1007/s10549-015-3291-9.CrossRefPubMed

55.

Purcell JW, Tanlimco SG, Hickson JA, et al. LRRC15 is a novel mesenchymal protein and stromal target for antibody-drug conjugates. Can Res. 2018;78:1457–70. https://doi.org/10.1158/0008-5472.CAN-18-0327.CrossRef

56.

Sebastian A, Hum NR, Martin KA, et al. Single-Cell Transcriptomic Analysis of Heterogeneity in Breast Cancer. Cancers. 2020;12:E1307. https://doi.org/10.3390/cancers12051307.CrossRefPubMed

57.

Cortez E, Roswall P, Pietras K. Functional subsets of mesenchymal cell types in the tumor microenvironment. Semin Cancer Biol. 2014;25:3–9. https://doi.org/10.1016/j.semcancer.2013.12.010.CrossRefPubMed

58.

Costa A, Kieffer Y, Scholer-Dahirel A, et al. Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer. Cancer Cell. 2018;33:1–17. https://doi.org/10.1016/j.ccell.2018.01.011.CrossRef

59.

Kojima Y, Acar A, Eaton EN, et al. Autocrine TGF-β and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci USA. 2010;107:20009–14. https://doi.org/10.1073/pnas.1013805107.CrossRefPubMedPubMedCentral

60.

Bartoschek M, Oskolkov N, Bocci M, et al. Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing. Nat Commun. 2018;9. https://doi.org/10.1038/s41467-018-07582-3.

61.

Raz Y, Cohen N, Shani O, et al. Bone marrow–derived fibroblasts are a functionally distinct stromal cell population in breast cancer. J Exp Med. 2018;215:3075–93. https://doi.org/10.1084/jem.20180818.CrossRefPubMedPubMedCentral

62.

Ghiabi P, Jiang J, Pasquier J, et al. Breast cancer cells promote a notch-dependent mesenchymal phenotype in endothelial cells participating to a pro-tumoral niche. J Transl Med. 2015;13:1–19. https://doi.org/10.1186/s12967-015-0386-3.CrossRef

63.

Weber, et al. Osteopontin Mediates an MZF1-TGF-β1-Dependent Transformation of Mesenchymal Stem Cells into Cancer Associated Fibroblasts in Breast Cancer. Oncog. 2015;34:4821–33. https://doi.org/10.1038/onc.2014.410.CrossRef

64.

Rønnov-Jessen L, Petersen OW, Koteliansky VE, et al. The origin of the myofibroblasts in breast cancer: Recapitulation of tumor environment in culture unravels diversity and implicates converted fibroblasts and recruited smooth muscle cells. J Clin Investig. 1995;95:859–73. https://doi.org/10.1172/JCI117736.CrossRefPubMedPubMedCentral

65.

Bochet L, Lehuédé C, Dauvillier S, et al. Adipocyte-derived fibroblasts promote tumor progression and contribute to the desmoplastic reaction in breast cancer. Can Res. 2013;73:5657–68. https://doi.org/10.1158/0008-5472.CAN-13-0530.CrossRef

66.

Nair N, Calle AS, Zahra MH, et al. A cancer stem cell model as the point of origin of cancer-associated fibroblasts in tumor microenvironment. Sci Rep. 2017;7:6838. https://doi.org/10.1038/s41598-017-07144-5.CrossRefPubMedPubMedCentral

67.

Bronzert DA, Pantazis P, Antoniades HN, et al. Synthesis and secretion of platelet-derived growth factor by human breast cancer cell lines. Proc Natl Acad Sci USA. 1987;84:5763–7. https://doi.org/10.1073/pnas.84.16.5763.CrossRefPubMedPubMedCentral

68.

Shao ZM, Nguyen M, Barsky SH. Human breast carcinoma desmoplasia is PDGF initiated. Oncog. 2000;19:4337–45. https://doi.org/10.1038/sj.onc.1203785.CrossRef

69.

Hendrayani SF, Al-Khalaf HH, Aboussekhra A. The cytokine il-6 reactivates breast stromal fibroblasts through transcription factor STAT3-dependent up-regulation of the RNA-binding protein AUF1. J Biol Chem. 2014;289:30962–76. https://doi.org/10.1074/jbc.M114.594044.CrossRefPubMedPubMedCentral

70.

Sharon Y, Raz Y, Cohen N, et al. Tumor-derived osteopontin reprograms normal mammary fibroblasts to promote inflammation and tumor growth in breast cancer. Can Res. 2015;75:963–73. https://doi.org/10.1158/0008-5472.CAN-14-1990.CrossRef

71.

Arcucci A, Ruocco MR, Granato G, et al. Cancer: An Oxidative Crosstalk between Solid Tumor Cells and Cancer Associated Fibroblasts. BioMed Res Int. 2016. https://doi.org/10.1155/2016/4502846.

72.

Li K, Liu T, Chen J, et al. Survivin in breast cancer-derived exosomes activates fibroblasts by upregulating SOD1, whose feedback promotes cancer proliferation and metastasis. J Biol Chem. 2020. jbc.RA120.013805. https://doi.org/10.1074/jbc.ra120.013805.

73.

Vu LT, Peng B, Zhang DX, et al. Tumor-secreted extracellular vesicles promote the activation of cancer-associated fibroblasts via the transfer of microRNA-125b. J Extracell Vesicles. 2019;8:1599680. https://doi.org/10.1080/20013078.2019.1599680.CrossRefPubMedPubMedCentral

74.

Chatterjee A, Jana S, Chatterjee S, et al. MicroRNA-222 reprogrammed cancer-associated fi broblasts enhance growth and metastasis of breast cancer. Br J Cancer. 2019. https://doi.org/10.1038/s41416-019-0566-7.CrossRefPubMedPubMedCentral

75.

Albrengues J, Bertero T, Grasset E, et al. Epigenetic switch drives the conversion of fibroblasts into proinvasive cancer-associated fibroblasts. Nat Commun. 2015;6:10204. https://doi.org/10.1038/ncomms10204.CrossRefPubMed

76.

Wang D dan, Li J, Sha H huan, et al. miR-222 confers the resistance of breast cancer cells to Adriamycin through suppression of p27kip1 expression. Gene. 2016;590:44–50. https://doi.org/10.1016/j.gene.2016.06.013.

77.

Costa A, Scholer-Dahirel A, Mechta-Grigoriou F. The role of reactive oxygen species and metabolism on cancer cells and their microenvironment. Semin Cancer Biol. 2014;25:23–32. https://doi.org/10.1016/j.semcancer.2013.12.007.CrossRefPubMed

78.

Manuscript A, Cells D, Cancer B. Role of Oxidative Stress and the Microenvironment in Breast Cancer Development and Progression. 2014;19:1–11. https://doi.org/10.1097/PPO.0000000000000007.Dendritic.CrossRef

79.

Xing F, Saidou J, Watabe K. Cancer associated fibroblasts (CAFs) in tumor microenvironment. Frontiers in bioscience (Landmark edition). 2010;15:166–79. https://doi.org/10.2741/3613.CrossRef

80.

Kwa MQ, Herum KM, Brakebusch C. Cancer-associated fibroblasts: how do they contribute to metastasis? Clin Exp Metas. 2019;36:71–86. https://doi.org/10.1007/s10585-019-09959-0.CrossRef

81.

Motrescu ER, Rio MC. Cancer cells, adipocytes and matrix metalloproteinase 11: A vicious tumor progression cycle. Biol Chem. 2008;389:1037–41. https://doi.org/10.1515/BC.2008.110.CrossRefPubMed

82.

Park J, Euhus DM, Scherer PE. Paracrine and endocrine effects of adipose tissue on cancer development and progression. Endocr Rev. 2011;32:550–70. https://doi.org/10.1210/er.2010-0030.CrossRefPubMedPubMedCentral

83.

Potenta S, Zeisberg E, Kalluri R. The role of endothelial-to-mesenchymal transition in cancer progression. Br J Cancer. 2008;99:1375–9. https://doi.org/10.1038/sj.bjc.6604662.CrossRefPubMedPubMedCentral

84.

Zeisberg EM, Potenta S, Xie L, et al. Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Can Res. 2007;67:10123–8. https://doi.org/10.1158/0008-5472.CAN-07-3127.CrossRef

85.

Yeon JH, Jeong HE, Seo H, et al. Cancer-derived exosomes trigger endothelial to mesenchymal transition followed by the induction of cancer-associated fibroblasts. Acta Biomater. 2018;76:146–53. https://doi.org/10.1016/j.actbio.2018.07.001.CrossRefPubMed

86.

Chaturvedi P, Gilkes DM, Wong CCL, et al. Hypoxia-inducible factor-dependent breast cancer-mesenchymal stem cell bidirectional signaling promotes metastasis. J Clin Investig. 2013;123:189–205. https://doi.org/10.1172/JCI64993.CrossRefPubMed

87.

Spaeth E, Klopp A, Dembinski J, et al. Inflammation and tumor microenvironments: Defining the migratory itinerary of mesenchymal stem cells. Gene Ther. 2008;15:730–8. https://doi.org/10.1038/gt.2008.39.CrossRefPubMed

88.

Shi Y, Du L, Lin L, et al. Tumour-associated mesenchymal stem/stromal cells: Emerging therapeutic targets. Nat Rev Drug Discovery. 2016;16:35–52. https://doi.org/10.1038/nrd.2016.193.CrossRefPubMed

89.

Sewell-Loftin MK, Bayer SVH, Crist E, et al. Cancer-associated fibroblasts support vascular growth through mechanical force. Sci Rep. 2017;7:1–12. https://doi.org/10.1038/s41598-017-13006-x.CrossRef

90.

Wobus M, List C, Dittrich T, et al. Breast carcinoma cells modulate the chemoattractive activity of human bone marrow-derived mesenchymal stromal cells by interfering with CXCL12. Int J Cancer. 2015;136:44–54. https://doi.org/10.1002/ijc.28960.CrossRefPubMed

91.

Jahn SC, Law ME, Corsino PE, et al. An in vivo model of epithelial to mesenchymal transition reveals a mitogenic switch. Cancer Lett. 2012;326:183–90. https://doi.org/10.1016/j.canlet.2012.08.013.CrossRefPubMedPubMedCentral

92.

Paunescu V, Bojin FM, Tatu CA, et al. Tumour-associated fibroblasts and mesenchymal stem cells: More similarities than differences. J Cell Mol Med. 2011;15:635–46. https://doi.org/10.1111/j.1582-4934.2010.01044.x.CrossRefPubMed

93.

Del Valle PR, Milani C, Brentani MM, et al. Transcriptional profile of fibroblasts obtained from the primary site, lymph node and bone marrow of breast cancer patients. Genet Mol Biol. 2014;37:480–9. https://doi.org/10.1590/S1415-47572014000400002.CrossRefPubMedPubMedCentral

94.

Mishra PJ, Mishra PJ, Humeniuk R, et al. Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Can Res. 2008;68:4331–9. https://doi.org/10.1158/0008-5472.CAN-08-0943.CrossRef

95.

Pasanen I, Lehtonen S, Sormunen R, et al. Breast cancer carcinoma-associated fibroblasts differ from breast fibroblasts in immunological and extracellular matrix regulating pathways. Exp Cell Res. 2016;344:53–66. https://doi.org/10.1016/j.yexcr.2016.04.016.CrossRefPubMed

96.

Heneberg P. Paracrine tumor signaling induces transdifferentiation of surrounding fibroblasts. Crit Rev Oncol/Hematol. 2016;97:303–11. https://doi.org/10.1016/j.critrevonc.2015.09.008.CrossRef

97.

Labovsky V, Martinez LM, Davies KM, et al. Association Between Ligands and Receptors Related to the Progression of Early Breast Cancer in Tumor Epithelial and Stromal Cells. Clin Breast Cancer. 2015;15:e13–21. https://doi.org/10.1016/j.clbc.2014.05.006.CrossRefPubMed

98.

Cirri P, Chiarugi P. Cancer-associated-fibroblasts and tumour cells: A diabolic liaison driving cancer progression. Cancer Metastasis Rev. 2012;31:195–208. https://doi.org/10.1007/s10555-011-9340-x.CrossRefPubMed

99.

Neel J-C, Humbert L, Lebrun J-J. The Dual Role of TGFβ in Human Cancer: From Tumor Suppression to Cancer Metastasis. ISRN Mol Biol. 2012;2012:1–28. https://doi.org/10.5402/2012/381428.CrossRef

100.

Principe DR, Doll JA, Bauer J, et al. TGF-β: Duality of function between tumor prevention and carcinogenesis. J Natl Cancer Inst. 2014;106:1–16. https://doi.org/10.1093/jnci/djt369.CrossRef

101.

Knudson KM, Hicks KC, Luo X, et al. M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine. OncoImmunology. 2018;7:1–14. https://doi.org/10.1080/2162402X.2018.1426519.CrossRef

102.

Boyd N, Berman H, Zhu J, et al. The origins of breast cancer associated with mammographic density: A testable biological hypothesis. Breast Cancer Res. 2018;20:1–13. https://doi.org/10.1186/s13058-018-0941-y.CrossRef

103.

Nguyen DH, Oketch-Rabah HA, Illa-Bochaca I, et al. Radiation Acts on the Microenvironment to Affect Breast Carcinogenesis by Distinct Mechanisms that Decrease Cancer Latency and Affect Tumor Type. Cancer Cell. 2011;19:640–51. https://doi.org/10.1016/j.ccr.2011.03.011.CrossRefPubMedPubMedCentral

104.

Kuperwasser C, Chavarria T, Wu M, et al. From The Cover: Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci. 2004;101:4966–71. https://doi.org/10.1073/pnas.0401064101.CrossRefPubMedPubMedCentral

105.

Shekhar MPV, Werdell J, Santner SJ, et al. Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation: Implications for tumor development and progression. Can Res. 2001;61:1320–6.

106.

Wang B, Xi C, Liu M, et al. Breast fibroblasts in both cancer and normal tissues induce phenotypic transformation of breast cancer stem cells : a preliminary study. 2018:1–19. https://doi.org/10.7717/peerj.4805.

107.

Acharyya S, Oskarsson T, Vanharanta S, et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. cell. 2012. https://doi.org/10.1016/j.cell.2012.04.042.

108.

Orimo A, Gupta PB, Sgroi DC, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005;121:335–48. https://doi.org/10.1016/j.cell.2005.02.034.CrossRefPubMed

109.

Liao D, Luo Y, Markowitz D, et al. Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS ONE. 2009;4:e7965. https://doi.org/10.1371/journal.pone.0007965.CrossRefPubMedPubMedCentral

110.

Sjöberg E, Augsten M, Bergh J, et al. Expression of the chemokine CXCL14 in the tumour stroma is an independent marker of survival in breast cancer. Br J Cancer. 2016;114:1117–24. https://doi.org/10.1038/bjc.2016.104.CrossRefPubMedPubMedCentral

111.

Sjöberg E, Meyrath M, Milde L, et al. A novel ACKR2-Dependent role of fibroblast-derived CXCL14 in epithelial-to-mesenchymal transition and metastasis of breast cancer. Clin Cancer Res. 2019;25:3702–17. https://doi.org/10.1158/1078-0432.CCR-18-1294.CrossRefPubMed

112.

Allaoui R, Bergenfelz C, Mohlin S, et al. Cancer-associated fibroblast-secreted CXCL16 attracts monocytes to promote stroma activation in triple-negative breast cancers. Nat Commun. 2016;7:13050. https://doi.org/10.1038/ncomms13050.CrossRefPubMedPubMedCentral

113.

Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. J Exp Med. 2014;211:1503–23. https://doi.org/10.1084/jem.20140692.CrossRefPubMedPubMedCentral

114.

Karnoub AE1, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R WR. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nat. 2007.

115.

Suh J, Kim DH, Lee YH, et al. Fibroblast growth factor-2, derived from cancer-associated fibroblasts, stimulates growth and progression of human breast cancer cells via FGFR1 signaling. Mol carcinog. 2020:1–13. https://doi.org/10.1002/mc.23233.

116.

Wu X, Zahari MS, Renuse S, et al. Quantitative phosphoproteomic analysis reveals reciprocal activation of receptor tyrosine kinases between cancer epithelial cells and stromal fibroblasts. Clin Proteomics. 2018;15:21. https://doi.org/10.1186/s12014-018-9197-x.CrossRefPubMedPubMedCentral

117.

DeClerck YA, Pienta KJ, Woodhouse EC, et al. The tumor microenvironment at a turning point knowledge gained over the last decade, and challenges and opportunities ahead: A white paper from the NCI TME network. Can Res. 2017;77:1051–9. https://doi.org/10.1158/0008-5472.CAN-16-1336.CrossRef

118.

Qiu W, Hu M, Sridhar A, et al. No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nat Genet. 2008;40:650–5. https://doi.org/10.1038/ng.117.CrossRefPubMedPubMedCentral

119.

Jang I, Beningo KA. Integrins, CAFs and Mechanical Forces in the Progression of Cancer. Cancers. 2019;11:721. https://doi.org/10.3390/cancers11050721.CrossRefPubMedCentral

120.

Wang Z, Xiong S, Mao Y, et al. Periostin promotes immunosuppressive pre-metastatic niche formation to facilitate breast tumor metastasis. J Pathol. 2016;239:484–95.CrossRefPubMed

121.

Huang W, Chiquet-Ehrismann R, Orend G, et al. Interference of tenascin-C with syndecan-4 binding to fibronectin blocks cell adhesion and stimulates tumor cell proliferation. Can Res. 2001;61:8586–94.

122.

Labovsky V, Martinez LM, Davies KM, et al. Prognostic significance of TRAIL-R3 and CCR-2 expression in tumor epithelial cells of patients with early breast cancer. BMC Cancer. 2017;17:280. https://doi.org/10.1186/s12885-017-3259-8.CrossRefPubMedPubMedCentral

123.

Martinez-Outschoorn UE, Balliet RM, Rivadeneira DB, et al. Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: A new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell Cycle. 2010;9:3256–76. https://doi.org/10.4161/cc.9.16.12553.CrossRefPubMedPubMedCentral

124.

Sanford-Crane H, Abrego J, Sherman MH. Fibroblasts as Modulators of Local and Systemic Cancer Metabolism. Cancers. 2019;11:619. https://doi.org/10.3390/cancers11050619.CrossRefPubMedCentral

125.

Pavlides S, Whitaker-Menezes D, Castello-Cros R, et al. The reverse Warburg effect: Aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle. 2009;8:3984–4001. https://doi.org/10.4161/cc.8.23.10238.CrossRefPubMed

126.

Sotgia F, Martinez-Outschoorn UE, Pavlides S, et al. Understanding the Warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment. Breast Cancer Res. 2011;13:1–13. https://doi.org/10.1186/bcr2892.CrossRef

127.

Fu Y, Liu S, Yin S, et al. The reverse Warburg effect is likely to be an Achilles’ heel of cancer that can be exploited for cancer therapy. Oncotarget. 2017;8:57813–25. https://doi.org/10.18632/oncotarget.18175.

128.

Becker LM, O’Connell JT, Vo AP, et al. Epigenetic Reprogramming of Cancer-Associated Fibroblasts Deregulates Glucose Metabolism and Facilitates Progression of Breast Cancer. Cell Rep. 2020;31:107701. https://doi.org/10.1016/j.celrep.2020.107701.CrossRefPubMedPubMedCentral

129.

Eiro N, González L, Martínez-Ordoñez A, et al. Cancer-associated fibroblasts affect breast cancer cell gene expression, invasion and angiogenesis. Cell Oncol. 2018:1–10. https://doi.org/10.1007/s13402-018-0371-y.

130.

Lappano R, Rigiracciolo DC, Belfiore A, et al. Cancer associated fibroblasts: role in breast cancer and potential as therapeutic targets. Expert Opinion on Therapeutic Targets. 2020;24:559–72. https://doi.org/10.1080/14728222.2020.1751819.CrossRefPubMed

131.

Yu Y, Xiao CH, Tan LD, et al. Cancer-associated fibroblasts induce epithelial-mesenchymal transition of breast cancer cells through paracrine TGF-β signalling. Br J Cancer. 2014;110:724–32. https://doi.org/10.1038/bjc.2013.768.CrossRefPubMed

132.

Matà R, Palladino C, Nicolosi ML, et al. IGF-I induces upregulation of DDR1 collagen receptor in breast cancer cells by suppressing MIR-199a-5p through the PI3K/AKT pathway. Oncotarget. 2016;7:7683–700. https://doi.org/10.18632/oncotarget.6524.

133.

Dumont N, Liu B, Defilippis RA, et al. Breast fibroblasts modulate early dissemination, tumorigenesis, and metastasis through alteration of extracellular matrix characteristics. Neoplasia (United States). 2013;15:249–62. https://doi.org/10.1593/neo.121950.CrossRef

134.

Wang JM, Deng X, Gong W, et al. Chemokines and their role in tumor growth and metastasis. J Immunol Methods. 1998;220:1–17. https://doi.org/10.1016/S0022-1759(98)00128-8.CrossRefPubMed

135.

Primac I, Maquoi E, Blacher S, et al. Stromal integrin α11 regulates PDGFRβ signaling and promotes breast cancer progression. J Clin Investig. 2019;129:4609–28. https://doi.org/10.1172/JCI125890.CrossRefPubMedPubMedCentral

136.

Tyan SW, Kuo WH, Huang CK, et al. Breast cancer cells induce cancer-associated fibroblasts to secrete hepatocyte growth factor to enhance breast tumorigenesis. PLoS ONE. 2011;6:1–9. https://doi.org/10.1371/journal.pone.0015313.CrossRef

137.

Osuala KO, Sameni M, Shah S, et al. Il-6 signaling between ductal carcinoma in situ cells and carcinoma-associated fibroblasts mediates tumor cell growth and migration. BMC Cancer. 2015;15. https://doi.org/10.1186/s12885-015-1576-3.

138.

Studebaker AW, Storci G, Werbeck JL, et al. Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner. Can Res. 2008;68:9087–95. https://doi.org/10.1158/0008-5472.CAN-08-0400.CrossRef

139.

Liu Y, Yang Y, Du J, et al. MiR-3613–3p from carcinoma-associated fibroblasts exosomes promoted breast cancer cell proliferation and metastasis by regulating SOCS2 expression. IUBMB Life. 2020:1–10. https://doi.org/10.1002/iub.2292.

140.

Donnarumma E, Fiore D, Nappa M, et al. Cancer-associated fibroblasts release exosomal microRNAs that dictate an aggressive phenotype in breast cancer. Oncotarget. 2017;8:19592–608. https://doi.org/10.18632/oncotarget.14752.

141.

Gaggioli C, Hooper S, Hidalgo-Carcedo C, et al. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat Cell Biol. 2007;9:1392–400. https://doi.org/10.1038/ncb1658.CrossRefPubMed

142.

Attieh Y, Clark AG, Grass C, et al. Cancer-associated fibroblasts lead tumor invasion through integrin-β3-dependent fibronectin asse. J Cell Biol. 2017;216:3509–20. https://doi.org/10.1083/jcb.201702033.CrossRefPubMedPubMedCentral

143.

Nabeshima K, Inoue T, Shimao Y, et al. Matrix metalloproteinases in tumor invasion: Role for cell migration. Pathol Int. 2002;52:255–64. https://doi.org/10.1046/j.1440-1827.2002.01343.x.CrossRefPubMed

144.

Nelson AR, Fingleton B, Rothenberg ML, et al. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol. 2017;18:1135–49.CrossRef

145.

Matsumura Y, Ito Y, Mezawa Y, et al. Stromal fibroblasts induce metastatic tumor cell clusters via epithelial–mesenchymal plasticity. Life Sci Alliance. 2019;2:1–24. https://doi.org/10.26508/lsa.201900425.

146.

Duda DG, Duyverman AMMJ, Kohno M, et al. Malignant cells facilitate lung metastasis by bringing their own soil. Proc Natl Acad Sci USA. 2010;107:21677–82. https://doi.org/10.1073/pnas.1016234107.CrossRefPubMedPubMedCentral

147.

Psailaa B, Kaplana RN, Port ER, et al. Priming the “soil” for breast cancer metastasis: The Pre-Metastatic Niche. Breast Dis. 2006;26:65–74. https://doi.org/10.3233/bd-2007-26106.CrossRef

148.

Ursini-Siegel J, Siegel PM. The influence of the pre-metastatic niche on breast cancer metastasis. Cancer Lett. 2016;380:281–8. https://doi.org/10.1016/j.canlet.2015.11.009.CrossRefPubMed

149.

Feng T, Zhang P, Sun Y, et al. High throughput sequencing identifies breast cancer-secreted exosomal LncRNAs initiating pulmonary pre-metastatic niche formation. Gene. 2019;710:258–64. https://doi.org/10.1016/j.gene.2019.06.004.CrossRefPubMed

150.

Taverna S, Giusti I, D’ascenzo S, et al. Breast cancer derived extracellular vesicles in bone metastasis induction and their clinical implications as biomarkers. Int J Mol Sci. 2020;21:1–21. https://doi.org/10.3390/ijms21103573.

151.

Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nat. 2005;438:820–7. https://doi.org/10.1038/nature04186.CrossRef

152.

Cox TR, Bird D, Baker A, et al. LOX-Mediated Collagen Crosslinking Is Responsible for Fibrosis-Enhanced Metastasis. Can Res. 2013;73:1721–32. https://doi.org/10.1158/0008-5472.CAN-12-2233.CrossRef

153.

Malanchi I, Santamaria-Martínez A, Susanto E, et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nat. 2012;481:85–91. https://doi.org/10.1038/nature10694.CrossRef

154.

Houthuijzen JM, Jonkers J. Cancer-associated fibroblasts as key regulators of the breast cancer tumor microenvironment. Cancer Metastasis Rev. 2018;37:577–97. https://doi.org/10.1007/s10555-018-9768-3.CrossRefPubMed

155.

Zhang Y and Ertl HC. Depletion of FAP+ cells reduces immunosuppressive cells and improves metabolism and functions CD8+T cells within tumors. Oncotarget. 2016;7:23282–99. https://doi.org/10.18632/oncotarget.7818.

156.

Zhang J, Pang Y, Xie T, et al. CXCR4 antagonism in combination with IDO1 inhibition weakens immune suppression and inhibits tumor growth in mouse breast cancer bone metastases. OncoTargets Ther. 2019;12:4985–92. https://doi.org/10.2147/OTT.S200643.CrossRef

157.

Xia Q, Zhang FF, Geng F, et al. Improvement of anti-tumor immunity of fibroblast activation protein α based vaccines by combination with cyclophosphamide in a murine model of breast cancer. Cell Immunol. 2016;310:89–98. https://doi.org/10.1016/j.cellimm.2016.08.006.CrossRefPubMed

158.

Kieffer Y, Hocine HR, Gentric G, et al. Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer. Cancer Discov. 2020;33:CD-19–1384. https://doi.org/10.1158/2159-8290.cd-19-1384.

159.

Gok Yavuz B, Gunaydin G, Gedik ME, et al. Cancer associated fibroblasts sculpt tumour microenvironment by recruiting monocytes and inducing immunosuppressive PD-1 + TAMs. Sci Rep. 2019;9:1–15. https://doi.org/10.1038/s41598-019-39553-z.CrossRef

160.

Roca H, Varcos ZS, Sud S, et al. CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization. J Biol Chem. 2009;284:34342–54. https://doi.org/10.1074/jbc.M109.042671.CrossRefPubMedPubMedCentral

161.

Mulholland BS, Forwood MR, Morrison NA. Monocyte Chemoattractant Protein-1 (MCP-1/CCL2) Drives Activation of Bone Remodelling and Skeletal Metastasis. Curr Osteoporos Rep. 2019;17:538–47. https://doi.org/10.1007/s11914-019-00545-7.CrossRefPubMedPubMedCentral

162.

Khalid A, Wolfram J, Ferrari I, et al. Recent Advances in Discovering the Role of CCL5 in Metastatic Breast Cancer. Mini-Reviews Med Chem. 2015;15:1063–72. https://doi.org/10.2174/138955751513150923094709.CrossRef

163.

Swamydas M, Ricci K, Rego SL, et al. Mesenchymal stem cell-derived CCL-9 and CCL-5 promote mammary tumor cell invasion and the activation of matrix metalloproteinases. Cell Adhes Migr. 2013;7:315–24. https://doi.org/10.4161/cam.25138.CrossRef

164.

Ouyang L, Chang W, Fang B, et al. Estrogen-induced SDF-1α production promotes the progression of ER-negative breast cancer via the accumulation of MDSCs in the tumor microenvironment. Sci Rep. 2016;6:39541. https://doi.org/10.1038/srep39541.CrossRefPubMedPubMedCentral

165.

Shou D, Wen L, Song Z, et al. Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies. Oncotarget. 2016;7:64505–11. https://doi.org/10.18632/oncotarget.11352.

166.

Stüber T, Monjezi R, Wallstabe L, et al. Inhibition of TGF- β- Receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer. J ImmunoTher Cancer. 2020;8:1–7. https://doi.org/10.1136/jitc-2020-000676.CrossRef

167.

Hargadon K. Dysregulation of TGFβ1 Activity in Cancer and Its Influence on the Quality of Anti-Tumor Immunity. J Clin Med. 2016;5:76. https://doi.org/10.3390/jcm5090076.CrossRefPubMedCentral

168.

Silzle T, Kreutz M, Dobler MA, et al. Tumor-associated fibroblasts recruit blood monocytes into tumor tissue. Eur J Immunol. 2003;33:1311–20. https://doi.org/10.1002/eji.200323057.CrossRefPubMed

169.

Cohen N, Shani O, Raz Y, et al. Fibroblasts drive an immunosuppressive and growth-promoting microenvironment in breast cancer via secretion of Chitinase 3-like 1. Oncog. 2017;36:4457–68. https://doi.org/10.1038/onc.2017.65.CrossRef

170.

Piersma B, Hayward MK and Weaver VM. Fibrosis and cancer: A strained relationship. Biochimica et Biophysica Acta - Rev Cancer. 2020;1873. https://doi.org/10.1016/j.bbcan.2020.188356.

171.

Glentis A, Oertle P, Mariani P, et al. Correction: Cancer-associated fibroblasts induce metalloprotease-independent cancer cell invasion of the basement membrane. Nat Commun. 2018;9:75005. https://doi.org/10.1038/s41467-018-03304-x.CrossRef

172.

Yamashita M, Ogawa T, Zhang X, et al. Role of stromal myofibroblasts in invasive breast cancer: Stromal expression of alpha-smooth muscle actin correlates with worse clinical outcome. Breast Cancer. 2012;19:170–6. https://doi.org/10.1007/s12282-010-0234-5.CrossRefPubMed

173.

Paulsson J, Sjöblom T, Micke P, et al. Prognostic significance of stromal platelet-derived growth factor β-receptor expression in human breast cancer. Am J Pathol. 2009;175:334–41. https://doi.org/10.2353/ajpath.2009.081030.CrossRefPubMedPubMedCentral

174.

Ariga N, Sato E, Ohuchi N, et al. Stromal expression of fibroblast activation protein / seprase, a cell membrane serine proteinase and gelatinase, is associated with longer survival in patients with invasive ductal. Int J Cancer. 2001;95:67–72. https://doi.org/10.1002/1097-0215(20010120)95:1%3c67::aid-ijc1012%3e3.0.co;2-u.CrossRefPubMed

175.

Kim HM, Jung WH, Koo JS. Expression of cancer-associated fibroblast related proteins in metastatic breast cancer: an immunohistochemical analysis. J Transl Med. 2015;13:222. https://doi.org/10.1186/s12967-015-0587-9.CrossRefPubMedPubMedCentral

176.

Ao Z, Shah SH, Machlin LM, et al. Identification of cancer-associated fibroblasts in circulating blood from patients with metastatic breast cancer. Can Res. 2015;75:4681–7. https://doi.org/10.1158/0008-5472.CAN-15-1633.CrossRef

177.

Schoppmann SF, Berghoff A, Dinhof C, et al. Podoplanin-expressing cancer-associated fibroblasts are associated with poor prognosis in invasive breast cancer. Breast Cancer Res Treat. 2012;134:237–44. https://doi.org/10.1007/s10549-012-1984-x.CrossRefPubMed

178.

Cai D, Wu X, Hong T, et al. CD61+ and CAF+ were found to be good prognosis factors for invasive breast cancer patients. Pathol Res Pract. 2017;213:1296–301. https://doi.org/10.1016/j.prp.2017.06.016.CrossRefPubMed

179.

Amornsupak K, Jamjuntra P, Warnnissorn M, et al. High ASMA+Fibroblasts and Low Cytoplasmic HMGB1+Breast Cancer Cells Predict Poor Prognosis. Clin Breast Cancer. 2017;17:441–52. https://doi.org/10.1016/j.clbc.2017.04.007.CrossRefPubMed

180.

Brechbuhl HM, Barrett AS, Kopin E, et al. Fibroblast subtypes define a metastatic matrisome in breast cancer. JCI Insight. 2020;5:1–16. https://doi.org/10.1172/jci.insight.130751.CrossRef

181.

Martinez LM, Labovsky V, De Lujan CM, et al. CD105 expression on CD34-negative spindle-shaped stromal cells of primary tumor is an unfavorable prognostic marker in early breast cancer patients. PLoS ONE. 2015;10:1993–6. https://doi.org/10.1371/journal.pone.0121421.CrossRef

182.

Labovsky V, Martinez LM, Calcagno M de L, et al. Interleukin-6 receptor in spindle-shaped stromal cells, a prognostic determinant of early breast cancer. Tumor Biol. 2016;37:13377–84. https://doi.org/10.1007/s13277-016-5268-7.

183.

Wallace JA, Li F, Leone G, et al. Pten in the breast tumor microenvironment: Modeling tumor-stroma coevolution. Can Res. 2011;71:1203–7. https://doi.org/10.1158/0008-5472.CAN-10-3263.CrossRef

184.

Tchou J, Kossenkov AV, Chang L, et al. Human breast cancer associated fibroblasts exhibit subtype specific gene expression profiles. BMC Med Genomics. 2012;5:39. https://doi.org/10.1186/1755-8794-5-39.CrossRefPubMedPubMedCentral

185.

Busch S, Andersson D, Bom E, et al. Cellular organization and molecular differentiation model of breast cancer-associated fibroblasts. Mol Cancer. 2017;16:1–12. https://doi.org/10.1186/s12943-017-0642-7.CrossRef

186.

Konieczkowski DJ, Johannessen CM, Garraway LA, et al. A convergence-based framework for cancer drug resistance. Cancer Cell. 2019;33:801–15. https://doi.org/10.1016/j.ccell.2018.03.025.A.CrossRef

187.

Valkenburg KC, De Groot AE, Pienta KJ. Targeting the tumour stroma to improve cancer therapy. Nat Rev Clin Oncol. 2018. https://doi.org/10.1038/s41571-018-0007-1.CrossRefPubMedPubMedCentral

188.

Loeffler M, Krüger JA, Niethammer AG, et al. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Investig. 2009;119:421–421. https://doi.org/10.1172/jci26532c1.CrossRefPubMedCentral

189.

Fang J, Xiao L, Joo K Il, et al. A potent immunotoxin targeting fibroblast activation protein for treatment of breast cancer in mice. Int J Cancer. 2016;138:1013–23. https://doi.org/10.1002/ijc.29831.

190.

Su S, Chen J, Yao H, et al. CD10+GPR77+ Cancer-Associated Fibroblasts Promote Cancer Formation and Chemoresistance by Sustaining Cancer Stemness. Cell. 2018;172(841–856):e16. https://doi.org/10.1016/j.cell.2018.01.009.CrossRef

191.

Boesch M, Onder L, Cheng HW, et al. Interleukin 7-expressing fibroblasts promote breast cancer growth through sustenance of tumor cell stemness. OncoImmunology. 2018;7:e1414129. https://doi.org/10.1080/2162402X.2017.1414129.CrossRefPubMedPubMedCentral

192.

Chauhan VP, Martin JD, Liu H, et al. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun. 2013;4:2516. https://doi.org/10.1038/ncomms3516.CrossRefPubMed

193.

Hu C, Liu X, Ran W, et al. Regulating cancer associated fibroblasts with losartan-loaded injectable peptide hydrogel to potentiate chemotherapy in inhibiting growth and lung metastasis of triple negative breast cancer. Biomaterials. 2017;144:60–72. https://doi.org/10.1016/j.biomaterials.2017.08.009.CrossRefPubMed

194.

Ryan D, Koziol J, ElShamy WM. Targeting AXL and RAGE to prevent geminin overexpression-induced triple-negative breast cancer metastasis. Sci Rep. 2019;9:1–19. https://doi.org/10.1038/s41598-019-55702-w.CrossRef

195.

Egeland EV, Boye K, Park D, et al. Prognostic significance of S100A4-expression and subcellular localization in early-stage breast cancer. Breast Cancer Res Treat. 2017;162:127–37. https://doi.org/10.1007/s10549-016-4096-1.CrossRefPubMed

196.

Boye K, Mælandsmo GM. S100A4 and metastasis: A small actor playing many roles. Am J Pathol. 2010;176:528–35. https://doi.org/10.2353/ajpath.2010.090526.CrossRefPubMedPubMedCentral

197.

Leconet W, Chentouf M, Du Manoir S, et al. Therapeutic activity of anti-AXL antibody against triple-negative breast cancer patient-derived xenografts and metastasis. Clin Cancer Res. 2017;23:2806–16. https://doi.org/10.1158/1078-0432.CCR-16-1316.CrossRefPubMed

198.

Wu X, Liu X, Koul S, et al. AXL kinase as a novel target for cancer therapy. Oncotarget. 2014;5:9546–63. https://doi.org/10.18632/oncotarget.2542.

199.

Park JS, Lee CH, Kim HK, et al. Suppression of the metastatic spread of breast cancer by DN10764 (AZD7762)-mediated inhibition of AXL signaling. Oncotarget. 2016;7:83308–18. https://doi.org/10.18632/oncotarget.13088.

200.

Wang C, Jin H, Wang N, et al. Gas6/Axl axis contributes to chemoresistance and metastasis in breast cancer through Akt/GSK-3β/β- catenin signaling. Theranostics. 2016;6:1205–19. https://doi.org/10.7150/thno.15083.CrossRefPubMedPubMedCentral

201.

Ye X, Li Y, Stawicki S, et al. An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies. Oncog. 2010;29:5254–64. https://doi.org/10.1038/onc.2010.268.CrossRef

202.

Hudson BI, Lippman ME. Targeting RAGE Signaling in Inflammatory Disease. Annu Rev Med. 2018;69:349–64. https://doi.org/10.1146/annurev-med-041316-085215.CrossRefPubMed

203.

El-Far AH, Sroga G, Al Jaouni SK, et al. Role and mechanisms of rage-ligand complexes and rage-inhibitors in cancer progression. Int J Mol Sci. 2020;21:1–21. https://doi.org/10.3390/ijms21103613.CrossRef

204.

Hollosi P, Yakushiji JK, Fong KSK, et al. Lysyl oxidase-like 2 promotes migration in noninvasive breast cancer cells but not in normal breast epithelial cells. Int J Cancer. 2009;125:318–27. https://doi.org/10.1002/ijc.24308.CrossRefPubMed

205.

Barker HE, Chang J, Cox TR, et al. LOXL2-mediated matrix remodeling in metastasis and mammary gland involution. Can Res. 2011;71:1561–72. https://doi.org/10.1158/0008-5472.CAN-10-2868.CrossRef

206.

Barker HE, Bird D, Lang G, et al. Tumor-secreted LOXL2 activates fibroblasts through fak signaling. Mol Cancer Res. 2013;11:1425–36. https://doi.org/10.1158/1541-7786.MCR-13-0033-T.CrossRefPubMed

207.

Takai K, Le A, Weaver VM, et al. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer. Oncotarget. 2016;7:82889–901. https://doi.org/10.18632/oncotarget.12658.

208.

Al-Harbi B, Hendrayani SF, Silva G, et al. Let-7b inhibits cancer-promoting effects of breast cancerassociated fibroblasts through IL-8 repression. Oncotarget. 2018;9:17825–38. https://doi.org/10.18632/oncotarget.24895.

209.

Casey TM, Eneman J, Crocker A, et al. Cancer associated fibroblasts stimulated by transforming growth factor beta1 (TGF-β1) increase invasion rate of tumor cells: A population study. Breast Cancer Res Treat. 2008;110:39–49. https://doi.org/10.1007/s10549-007-9684-7.CrossRefPubMed

210.

Rønnov-Jessen L PO. Induction of alpha-smooth muscle actin by transforming growth factor-beta 1 in quiescent human breast gland fibroblasts. Implications for myofibroblast generation in breast neoplasia. Lab Invest. 1993;68:696–707.

211.

Desmouliere A, Geinoz A, Gabbiani F, et al. Transforming growth factor-β1 induces α-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol. 1993;122:103–11. https://doi.org/10.1083/jcb.122.1.103.CrossRefPubMed

212.

Shi Y, Massagué J. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell. 2003;113:685–700. https://doi.org/10.1016/S0092-8674(03)00432-X.CrossRefPubMed

213.

Xu J, Lu Y, Qiu S, et al. A novel role of EMMPRIN/CD147 in transformation of quiescent fibroblasts to cancer-associated fibroblasts by breast cancer cells. Cancer Lett. 2013;335:380–6. https://doi.org/10.1016/j.canlet.2013.02.054.CrossRefPubMedPubMedCentral

Titel: Cancer-Associated Fibroblasts in the Breast Tumor Microenvironment
verfasst von: María Belén Giorello
Francisco Raúl Borzone
Vivian Labovsky
Flavia Valeria Piccioni
Norma Alejandra Chasseing
Publikationsdatum: 04.01.2021
Verlag: Springer US
Schlagwörter: Breast Cancer
Breast Cancer
Erschienen in: Journal of Mammary Gland Biology and Neoplasia / Ausgabe 2/2021
Print ISSN: 1083-3021
Elektronische ISSN: 1573-7039
DOI: https://doi.org/10.1007/s10911-020-09475-y

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Cancer-Associated Fibroblasts in the Breast Tumor Microenvironment

Abstract

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2021

Correction to: Breast Cancer Response to Therapy: Can microRNAs Lead the Way?

Epithelial p53 Status Modifies Stromal-Epithelial Interactions During Basal-Like Breast Carcinogenesis

Deep Learning Enables Individual Xenograft Cell Classification in Histological Images by Analysis of Contextual Features

A Method to Pre-Screen Rat Mammary Gland Whole-Mounts Prior To RNAscope

A Comparative Review of the Extrinsic and Intrinsic Factors Regulating Lactose Synthesis

A Comparative Review of the Cell Biology, Biochemistry, and Genetics of Lactose Synthesis

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie